TALEN

TALEN1-nfe2

ID
ZDB-TALEN-170123-1
Name
TALEN1-nfe2
Previous Names
None
Target
Target Sequence 1
5' - TCACCCACCTCTTATGAG - 3'
ZFIN BLAST NCBI BLAST Ensembl
Target Sequence 2
5' - TGACCACGTGTAGTCATG - 3'
ZFIN BLAST NCBI BLAST Ensembl
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
mi4002 nfe2
Expression
Gene expression in Wild Types + TALEN1-nfe2
No data available
Phenotype
Phenotype resulting from TALEN1-nfe2
No data available
Phenotype of all Fish created by or utilizing TALEN1-nfe2
Phenotype Fish Conditions Figures
whole organism anterior-posterior axis increased curvature, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. S4 from Williams et al., 2016
swim bladder uninflated, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1 from Williams et al., 2016
whole organism spi2 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism linc-nlrp12 expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism anterior-posterior axis increased curvature, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1,  Fig. S4 from Williams et al., 2016
heart contraction increased rate, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1 from Williams et al., 2016
whole organism dnajb9b expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
pericardium edematous, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1 from Williams et al., 2016
swim bladder inflation delayed, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1 from Williams et al., 2016
whole organism gpr19 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
whole organism gpr19 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism dnajb9b expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism slc35f4 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
whole organism cfap70 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
whole organism slc16a6a expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism slc35f4 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
heart contraction decreased rate, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1 from Williams et al., 2016
whole organism linc-nlrp12 expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism cyp4v2b expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
nucleate erythrocyte low saturation, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 2,  Fig. 3,  Fig. S1,  Fig. S4 from Williams et al., 2016
whole organism spi2 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
otolith mislocalised, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. S3 from Williams et al., 2016
whole organism cfap70 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism fhad1 expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism dhx40 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
blood circulation disrupted, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. S4 from Williams et al., 2016
whole organism spi2 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism cyp4v2b expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
whole organism slc16a6a expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism gpr19 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism dhx40 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
blood circulation disrupted, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1,  Fig. S4 from Williams et al., 2016
swim bladder inflation delayed, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. S3 from Williams et al., 2016
whole organism cyp4v2b expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
otolith mislocalised, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. S1 from Williams et al., 2016
whole organism dnajb9b expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
whole organism fhad1 expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
nucleate erythrocyte low saturation, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 2,  Fig. 3,  Fig. S4 from Williams et al., 2016
whole organism slc16a6a expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
whole organism cfap70 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism slc35f4 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: tert-butyl hydroperoxide Fig. 6 from Williams et al., 2016
whole organism dhx40 expression increased amount, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 6 from Williams et al., 2016
whole organism fhad1 expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
nucleate erythrocyte low saturation, abnormal nfe2mi4002/mi4002 (AB/TL) standard conditions Fig. 2,  Fig. 3,  Fig. S1,  Fig. S3,  Fig. S4 from Williams et al., 2016
whole organism linc-nlrp12 expression decreased amount, abnormal nfe2mi4002/mi4002 (AB/TL) chemical treatment by environment: diquat Fig. 6 from Williams et al., 2016
head kidney thromboblast decreased amount, abnormal nfe2mi4002/mi4002; la2Tg (AB/TL) control Fig. 2 from Rost et al., 2018
blood thrombocyte decreased amount, abnormal nfe2mi4002/mi4002; la2Tg (AB/TL) control Fig. 2 from Rost et al., 2018
head kidney thrombocyte decreased amount, abnormal nfe2mi4002/mi4002; la2Tg (AB/TL) control Fig. 2 from Rost et al., 2018
thrombocyte activation process quality, abnormal nfe2mi4002/mi4002; la2Tg (AB/TL) control Fig. 4 from Rost et al., 2018
whole organism viability, abnormal nfe2mi4002/+; fgami4007/mi4007 (AB/TL) standard conditions Fig. 2 from Hu et al., 2019
whole organism decreased life span, abnormal nfe2mi4002/mi4002; fgami4007/mi4007 (AB/TL) standard conditions Fig. 2 from Hu et al., 2019
whole organism viability, exacerbated nfe2mi4002/mi4002; fgami4007/mi4007 (AB/TL) standard conditions Fig. 2 from Hu et al., 2019
Citations
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.